|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
21,550,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1548 - $0.1548 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile InspireMD is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of vascular and coronary disease. Co.'s CGuard™ carotid embolic prevention system combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Co.'s MGuard™ Prime™ Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
50,000 |
469,995 |
505,495 |
| Total Buy Value |
$0 |
$126,540 |
$812,266 |
$880,036 |
| Total People Bought |
0 |
1 |
4 |
4 |
| Total Buy Transactions |
0 |
1 |
5 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shore Craig |
CFO and CAO |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
238,625 |
879,844 |
|
- |
|
| Verta Patrick |
EVP Clinical/Medical Affairs |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
85,720 |
228,460 |
|
- |
|
| Roubin Gary S |
Director |
– • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
29,032 |
471,163 |
|
- |
|
| Tommasoli Andrea |
Chief Operating Officer |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
238,625 |
495,078 |
|
- |
|
| Arnold Kathryn |
Director |
– • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
29,032 |
215,040 |
|
- |
|
| Slosman Marvin |
CEO and President |
• • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
563,499 |
1,852,119 |
|
- |
|
| Berman Michael |
Director |
– • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
29,032 |
232,042 |
|
- |
|
| Gleason Shane Thomas |
Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
238,625 |
514,365 |
|
- |
|
| Kester Thomas J |
Director |
– • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
29,032 |
296,075 |
|
- |
|
| Stuka Paul |
Director |
– • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
43,548 |
311,548 |
|
- |
|
| Kester Thomas J |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,183 |
267,043 |
|
- |
|
| Berman Michael |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,782 |
203,010 |
|
- |
|
| Roubin Gary S |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,229 |
442,131 |
|
- |
|
| Arnold Kathryn |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,661 |
186,008 |
|
- |
|
| Roubin Gary S |
Director |
– • – |
2023-11-30 |
4 |
B |
$2.53 |
$126,540 |
D/D |
50,000 |
438,902 |
2.39 |
- |
|
| Verta Patrick |
EVP Clinical/Medical AffairsOf |
• – – |
2023-10-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
142,740 |
|
- |
|
| Arnold Kathryn |
Director |
– • – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,364 |
184,347 |
|
- |
|
| Roubin Gary S |
Director |
– • – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,652 |
388,902 |
|
- |
|
| Berman Michael |
Director |
– • – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,106 |
199,228 |
|
- |
|
| Kester Thomas J |
Director |
– • – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,614 |
263,860 |
|
- |
|
| Gleason Shane Thomas |
Chief Commercial Officer |
• – – |
2023-08-28 |
4 |
A |
$0.00 |
$0 |
D/D |
19,290 |
275,740 |
|
- |
|
| Roubin Gary S |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,445 |
386,250 |
|
- |
|
| Berman Michael |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,351 |
196,122 |
|
- |
|
| Arnold Kathryn |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,772 |
182,983 |
|
- |
|
| Kester Thomas J |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,396 |
261,246 |
|
- |
|
133 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
